Screener
Rapport Therapeutics, Inc. RAPP Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:30 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333862
| Line item | For the six monthsended June 30, 2026 | For the six monthsended June 30, 2025 |
|---|---|---|
| Maturities of short-term investments | 123,481 | 100,033 |
| Purchases of property and equipment | (164) | (313) |
| Proceeds from sales of equipment | 193 | - |
| Net cash provided by investing activities | 63,541 | 43,627 |
| Cash flows from financing activities | ||
| Payment of deferred offering costs | (454) | (63) |
| Proceeds from exercise of stock options | 2,401 | 6 |
| Repurchase of unvested restricted common stock | (5) | (1) |
Item 1. Financial Statements.
FAQ
- What is Rapport Therapeutics, Inc.'s investing cash flow?
- Rapport Therapeutics, Inc. (RAPP) reported investing cash flow of $25.6M in Q2 2026.
- How has Rapport Therapeutics, Inc.'s investing cash flow changed year-over-year?
- Rapport Therapeutics, Inc.'s investing cash flow increased by 13.3% year-over-year, from $22.6M to $25.6M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Rapport Therapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude